Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J.,
Salvesen, G. S., & Roses, A. D. (1993). Apolipoprotein E: High-avidity binding to beta-
amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer dis-
ease. Proceedings of the National Academy of Sciences, USA, 90, 1977–1981.
Swanwick, G. R., Coen, R. F., Coakley, D., & Lawlor, B. A. (1998). Assessment of progres-
sion and prognosis in “possible” and “probable” Alzheimer’s disease. International
Journal of Geriatric Psychiatry, 13, 331–335.
Takeda, A., Clegg, A., Kirby, J., Picot, E., Payne, C., & Green, C. (2006). A systematic re-
view of the clinical effectiveness of donepezil, rivastigmine and galantamine on cogni-
tion, quality of life and adverse events in Alzheimer’s disease. International Journal of
Geriatric Psychiatry, 21, 17–28.
Tombaugh, T. N., & McIntyre, N. J. (1992). The Mini-Mental State Examination: A com-
prehensive review. Journal of the American Geriatrics Society, 40, 922–935.
Tran, M., Bedard, M., Molloy, D. W., Dubois, S., & Lever, J. A. (2003). Associations be-
tween psychotic symptoms and dependence in activities of daily living among older
adults with Alzheimer’s disease. International Psychogeriatrics, 15, 171–179.
Ueki, A., Shinjo, H., Shimode, H., Nakajima, T., & Morita, Y. (2001). Factors associated
with mortality in patients with early-onset Alzheimer’s disease: A 5-year longitudi-
nal study. International Journal of Geriatric Psychiatry, 16, 810–815.
van Duijn, C. M., Clayton, D., Chandra, V., Fratiglioni, L., Graves, A. B., Heyman, A., et al.
(1991). Familial aggregation of Alzheimer’s disease and related disorders: A collabora-
tive re-analysis of case-control studies (EURODEM Risk Factors Research Group). In-
ternational Journal of Epidemiology, 20, S13–S20.
Visser, P. J., Scheltens, P., & Verhey, F. R. (2005). Do MCI criteria in drug trials accurately
identify subjects with predementia Alzheimer’s disease? Journal of Neurology, Neuro-
surgery, and Psychiatry, 76, 1348–1354.
Visser, P. J., Verhey, F. R. J., Schelteng, P., Cruts, M., Ponds, R. W., & van Broeckhover,
C. L. (2002). Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively
mildly impaired subjects. Journal of Neurology, 249, 312–319.
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. O., et al.
(2004). Mild cognitive impairment: Beyond controversies, towards a consensus: Report
of the International Working Group on Mild Cognitive Impairment. Journal of Internal
Medicine, 256, 240–246.
Wing, J., Nixon, J., von Cranach, M., & Strauss, A. (1977). Further developments of the
“present state examination” and CATEGO system. Archiv fur Psychiatrie und Ner-
venkrankheiten, 224, 151–160.
Wisniewski, T., Golabek, A., Matsubara, E., Ghiso, J., & Frangione, B. (1993). Apolipopro-
tein E: Binding to soluble Alzheimer’s beta-amyloid. Biochemical and Biophysical Re-
search Communications, 90, 359–365.
Wolfson, C., Wolfson, D. B., Asgharian, M., M’Lan, C. E., Ostbye, T., Rockwood, K., et al.
(2001). A reevaluation of the duration of survival after the onset of dementia. New En-
gland Journal of Medicine, 344, 1111–1116.
World Health Organization. (2003). International statistical classification of diseases and re-
lated health problems (ICD-10, 2nd ed.). Geneva, Switzerland: Author.
Zhang, M. Y., Qu, G. Y., Katzman, R., Lu, E., Wang, Z. Y., Cha, G. J., et al. (1990). The
prevalence of dementia and Alzheimer’s disease in Shanghai, China: Impact of age,
gender, and education. Annals of Neurology, 27, 428–437.
366 E
VIDENCE
-B
ASED
H
EALTH
P
RACTICE